<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559842</url>
  </required_header>
  <id_info>
    <org_study_id>2017-15</org_study_id>
    <nct_id>NCT03559842</nct_id>
  </id_info>
  <brief_title>Sleeve-gastrectomy Efficacy in Morbid Obese Patient With a Focus on the Role of Inflammation</brief_title>
  <official_title>Sleeve-gastrectomy Efficacy in the Treatment of Metabolic and Vascular Dysfunction of Morbid Obese Patient With a Focus on the Role of Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the wide range of studies concerning the positive effects of bariatric surgery on
      metabolic state of morbid obese patient, it is necessary to further investigate the specific
      role of the &quot;sleeve-gastrectomy&quot; intervention, going not only to research results in terms of
      safety or efficacy on the treatment of comorbidities, but also aimed to understand whether
      the improvement of metabolic and cardiovascular parameters is due to total weight loss or
      rather to visceral fat loss, and how much of this improvement is attributable to changes in
      inflammatory status. The primary endpoint of the study is to evaluate the effect of
      sleeve-gastrectomy on metabolic parameters (glyco-lipidic assessment, vitamins),
      bone-remodelling parameters (vitamin D, parathormone) and cardiovascular parameters (blood
      pressure, flow-mediated dilation, indexed left ventricular mass, inter-ventricular septum,
      carotid intima-media thickness) in a large obese population on the basis of total weight loss
      (TWL), variation of visceral fat area (VFA), variation of peri-renal fat thickness and
      insulin resistance index (&quot;Homeostasis Model Assessment-insulin resistance&quot; - HOMA). In
      addition the investigators set themselves the objective of assessing whether the presence of
      comorbidities (diabetes and hypertension) can influence the effects of the intervention on
      the above parameters, and whether the levels of the NETs and of adipokines such as chemerin
      in the pre- and post-intervention can correlate with the metabolic-vascular dysfunction, and
      play a role in its eventual improvement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>flow-mediated dilation</measure>
    <time_frame>One year</time_frame>
    <description>ultrasound evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>obesity-related cardiomyopathy</measure>
    <time_frame>One year</time_frame>
    <description>cardiac ultrasonography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>One year</time_frame>
    <description>HOMA index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ectopic adiposity</measure>
    <time_frame>One year</time_frame>
    <description>ultrasound evaluation of visceral fat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>One year</time_frame>
    <description>high sensitivity C reactive protein, sclerostin, osteopontin, cathepsin K, IL-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>One year</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>carotid intima-media thickness</measure>
    <time_frame>One year</time_frame>
    <description>ultrasound evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>microcirculatory function</measure>
    <time_frame>One year</time_frame>
    <description>Laser-Doppler flowmetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>aortic stiffness</measure>
    <time_frame>One year</time_frame>
    <description>tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiovascular assessment</measure>
    <time_frame>One year</time_frame>
    <description>anti-hypertensive therapy variation (number of drugs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dyslipidemia</measure>
    <time_frame>One year</time_frame>
    <description>total cholesterol, triglycerides, HDL, LDL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>liver function</measure>
    <time_frame>One year</time_frame>
    <description>Evaluation of &quot;Non-alcoholic fatty liver disease&quot; (NAFLD) fibrosis score according to the following formula:
-1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×109/l) - 0.66 × albumin (g/dl).
Cutoffs:
NAFLD Score &lt; -1.455 = low grade fibrosis; NAFLD Score -1.455 - 0.675 = indeterminate score; NAFLD Score &gt; 0.675 = high grade fibrosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biliary acid and sterols assessment</measure>
    <time_frame>One year</time_frame>
    <description>laboratory analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone metabolism assessment</measure>
    <time_frame>One year</time_frame>
    <description>vitamin D, PTH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nutritional assessment</measure>
    <time_frame>One year</time_frame>
    <description>sideremia, vitamin B12, folates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adipose tissue quantification</measure>
    <time_frame>One year</time_frame>
    <description>bioimpedentiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adipokines</measure>
    <time_frame>One year</time_frame>
    <description>chemerin, leptin and adiponectin plasmatic dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NETs</measure>
    <time_frame>One year</time_frame>
    <description>&quot;Neutrophil extracellular traps&quot; dosage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory bone remodeling markers</measure>
    <time_frame>One year</time_frame>
    <description>sclerostin, osteopontin, cathepsin K</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macrophages commitment markers</measure>
    <time_frame>One year</time_frame>
    <description>interleukin-10</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Surgery patients</arm_group_label>
    <description>Obese patients undergoing laparoscopic sleeve gastrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgery patients</arm_group_label>
    <description>Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Morbid obese patients with BMI ≥ 40 kg / m2 (or ≥ 35 kg / m2 with at least one comorbidity)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - BMI ≥ 40 kg / m2 (or ≥ 35 kg / m2 with at least one comorbidity), aged between 18 and 65
        years.

        Exclusion Criteria:

          -  renal or hepatic impairment

          -  heart failure (New York Heart Association - NYHA II-IV)

          -  secondary causes of obesity

          -  major psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Graziana Lupattelli, Prof</last_name>
    <phone>00390755784023</phone>
    <email>graziana.lupattelli@unipg.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Internal Medicine</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graziana Lupattelli, Prof</last_name>
      <phone>00390755784023</phone>
      <email>graziana.lupattelli@unipg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>March 7, 2020</last_update_submitted>
  <last_update_submitted_qc>March 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Maria Anastasia Ricci</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

